Table 1 Patient characteristics and results of sequencing and D-HPLC

From: Detection of ABL kinase domain mutations with denaturing high-performance liquid chromatography

Patient #	Sex	Age (years)	Disease	Disease phase at initiating imatinib	Duration of imatinib treatment prior to analysis (weeks)	Best response to imatinib	Disease state at the time of analysis	Sequence Leipzig nucleotide exchange	Sequence Leipzig amino acid exchange	Sequence Portland	D-HPLC-5′	D-HPLC-3′	BCR-ABL/ABL ratio
1	m	64	CML	M-BC	17	CHR	Hematological relapse in M-BC	G1127A	E255K	E255K	MUT	WT	114
2	m	48	CML	CP2	0	CHR	Initial	WT	WT	ND	WT	WT	87
3	m	65	CML	CP1	39	CCR	Cytogenetic relapse	T1121C	Y253H	Y253H	MUT	WT	79
4	f	62	CML	AP	8	PHR	Hematological relapse in AP	C1308T	T315I	T315I	MUT	WT	17
5	f	53	CML	M-BC	4	NR	Hematological relapse in M-BC	C1308T	T315I	T315I	MUT	WT	66
6	m	46	CML	AP	10	PHR	Hematological relapse in AP	WT	WT	WT	WT	WT	117
7	f	62	CML	AP	26	PHR	PHR	A1128T	E255V	E255V	MUT	WT	68
8	m	55	CML	AP	0	NR	Initial	WT	WT	ND	WT	WT	113
9	m	52	CML	AP	37	CHR	Hematological relapse in AP	T1416C	M351T	M351T	WT	MUT	70
10	m	60	CML	L-BC	20	MCR	Hematological relapse in AP	A1315C	F317L	F317L	MUT	WT	Failed
11	f	47	CML	AP	29	CHR	Hematological relapse in AP	T1416C	M351T	M351T	WT	MUT	70
12	f	68	CML	CP2	10	CP	Stable disease	WT	WT	ND	WT	WT	78
13	f	69	CML	AP	33	PHR	Hematological relapse in AP	A1551G	H396R	H396R	WT	MUT	72
14	f	69	CML	L-BC	11	PHR	Hematological relapse in M-BC	WT	WT	ND	WT	WT	Failed
15	f	40	CML	M-BC	23	CHR	Hematological relapse in M-BC	WT	WT	ND	WT	WT	42
16	f	24	CML	M-BC	92	CHR	Hematological relapse in M-BC	T1121C	Y253H	Y253H	MUT	WT	67
17	f	60	CML	M-BC	8	NR	Initial	WT	WT	(T315I)^a	MUT	WT	23
18	f	59	CML	M-BC	29	PHR	Hematological relapse in M-BC	T1439A	F359I	F359I + S417Y^b	WT	MUT	Failed
19^c	f	59	ALL	CR2	52	Started in CR	Hematological relapse	T1439G	F359V	F359V	WT	MUT	ND
20^c	f	59	ALL	CR2	52	Started in CR	Hematological relapse	T1439G	F359V	F359V	WT	MUT	ND
21	m	53	CML	M-BC	3	NR	Initial	WT	WT	ND	WT	WT	13
22	m	65	ALL	2. relapse	8	CHR	Hematological relapse	T1121C	Y253H	Y253H	MUT	WT	Failed
23	m	52	CML	CP1	56	CHR	Hematological relapse in CP	WT	WT	ND	WT	WT	Failed
24	m	58	CML	M-BC	17	CHR	Hematological relapse in CP	WT	WT	ND	WT	WT	79
25	m	46	CML	AP	17	NR	Hematological relapse in AP	WT	WT	ND	WT	WT	Failed
26	m	73	CML	M-BC	63	CCR	Hematological relapse in M-BC	T1416C	M351T	M351T	MUT	WT	127
27	m	40	CML	CP1	17	PHR	Hematological relapse in CP	A1122T	Y253F	Y253F	MUT	WT	42
28	f	67	CML	CP1	15	CHR	Hematological relapse in CP	WT	WT	ND	WT	WT	63
29	f	56	CML	M-BC	5	NR	Initial	WT	WT	ND	WT	WT	134
30	m	57	CML	CP1	0	NN	Initial	WT	WT	ND	WT	WT	54

AP – accelerated phase; CHR – complete hematological remission; CP – chronic phase; L-BC – lymphoid blast crisis; M-BC – myeloid blast crisis; MUT – mutant; UNK – not known; NR – no response; PHR – partial hematological remission; WT – wild type.
^aIn patient #17, the mutation was detected only after cloning of PCR products and sequencing of individual clones.
^bAmino acid 417 was not included in the PCR product sequenced in Leipzig.
^c#19 (peripheral blood) and 20 (bone marrow) are from the same patient.

Back to article page

Table 1 Patient characteristics and results of sequencing and D-HPLC

Search

Quick links